We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Type
- ARTG (273)
- Cancellation by sponsor (188)
- Australian Public Assessment Report (AusPAR) (11)
- Prescription medicine registration (10)
- Section 14, TGO91 consent (10)
- Listed medicine compliance report (9)
- Prescription medicine decision summary (4)
- Designation or determination (1)
- Prescription medicine evaluation (1)
Date
- 2024 (27)
- 2023 (60)
- 2022 (44)
- 2021 (30)
- 2020 (41)
- 2019 (37)
- 2018 (14)
- 2017 (37)
- 2016 (9)
- 2015 (42)
- 2014 (24)
- 2013 (6)
- 2012 (15)
- 2011 (6)
- 2010 (7)
- 2009 (3)
- 2008 (9)
- 2007 (7)
- 2006 (5)
- 2004 (7)
- 2003 (6)
- 2002 (4)
- 2001 (3)
- 2000 (9)
- 1999 (1)
- 1998 (7)
- 1997 (2)
- 1996 (5)
- 1995 (2)
- 1994 (7)
- 1993 (3)
- 1992 (6)
- 1991 (22)
Results for
"[search-keyword]"
Sponsor content
507 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GASTROGRAFIN oral liquid bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Iberogast IBS + Digestive Relief softgel capsules.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EYLEA aflibercept 114.3 mg/mL solution for intravitreal injection pre-filled syringe with OcuClick dosing system.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Berocca energy effervescent tablets pineapple lime flavour.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Elevit Morning Sickness Relief.
-
Australian Public Assessment Report (AusPAR)Nubeqa has been approved to treat metastatic hormone-sensitive prostate cancer in combination with docetaxel.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Berocca Hydrate effervescent tablets Raspberry Blackcurrant flavour.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Berocca Hydrate effervescent tablets orange flavour.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EYLEA aflibercept 114.3 mg/mL solution for intravitreal injection vial with needle.